










Supplementary information








Structure-based classification predicts drug response in *EGFR*-mutant NSCLC

In the format provided by the
authors and unedited

Supplemental Table 1. Summary of compounds

EGFR TKI	Class	Primary Target	Binding	Structure
Erlotinib	first-generation	EGFR	non-covalent	
Gefitinib	first-generation	EGFR	non-covalent	
AZD3759	first-generation	EGFR	non-covalent	
Sapatinib	first-generation	EGFR	non-covalent	
Afatinib	second-generation	EGFR	covalent	
Dacomitinib	second-generation	EGFR	covalent	
Neratinib	second-generation	EGFR	covalent	
Pozotinib	second-generation	EGFR	covalent	

Tarlox-TKI	second-generation	EGFR	covalent	
CLN-081	Ex20ins Active	EGFR	covalent	
AZ5104	Ex20ins Active	EGFR	covalent	
Mobocertinib	Ex20ins Active	EGFR	covalent	
Osimertinib	third-generation	EGFR	covalent	
Nazartinib	third-generation	EGFR	covalent	
Olmutinib	third-generation	EGFR	covalent	
Rociletinib	third-generation	EGFR	covalent	
Naquotinib	third-generation	EGFR	covalent	

Lazertinib	third-generation	EGFR	covalent	
Ruboxistaurin	PKC	PKC	non-covalent	
Sotрастaurин	PKC	PKC	non-covalent	
Midostaurin	PKC	PKC	non-covalent	
CUDC-101	EGFR/HDAC	EGFR/HDAC	non-covalent	
Brigatinib	ALK	ALK	non-covalent	
AZD3463	ALK	ALK	non-covalent	

Supplemental Table 2. Summary of variable importance determined by CART including T790M-like mutations

Summary of variable importance		
Drug	Structure function group	Exon-based group
Erlotinib	78	22
Gefitinib	90	11
AZD3759	77	23
Sapatinib	77	23
Afatinib	75	25
Dacomitinib	75	25
Neratinib	66	34
Poziotinib	94	6
Tarlox-TKI	79	21
CLN-081	91	9
AZ5104	91	9
Mobocertinib	90	10
Osimertinib	87	14
Nazartinib	82	18
Olmutinib	89	11
Rociletinib	85	15
Naquotinib	78	22
Lazertinib	91	9

Supplemental Table 3. Summary of variable importance determined by CART without T790M-like mutations

Summary of variable importance		
Drug	Structure function group	Exon-based group
Erlotinib	85	3.75
Gefitinib	90	2.5
AZD3759	83	4.25
Sapatinib	77	5.5
Afatinib	80	5.25
Dacomitinib	83	4.25
Neratinib	51	12.25
Poziotinib	23	19.25
Tarlox-TKI	82	4.5
CLN-081	84	4.25
AZ5104	73	6.75
Mobocertinib	73	6.75
Osimertinib	88	5.5
Nazartinib	83	4.5
Olmutinib	85	3.75
Rociletinib	75	6.5
Naquotinib	82	4.5
Lazertinib	73	6.75

Supplemental Table 4: List of EGFR mutations and assigned subgroups used in manuscript

Classical-Like Mutations	PACC Mutations		Ex20 Loop Insertions		T790M-like Mutations	
			Near-loop	Far-loop	T790M-like-3S	T790M-like-3R
A702T	A750_I759del insPN	K757M L858R	A767_V769dup ASV	H773_V774 insNPH	Ex19del	Ex19del
A763insFQEA	E709_T710del insD	K757R	A767_S768ins TLA	H773_V774 insAH	T790M	T790M C797S
A763insLQEA	E709A	L718Q L718Q	S768_D770dup SVD		Ex19del	Ex19del
D761N	E709A G719A	Ex19del	S768_D770dup SVD	H773dupH V774_C775	T790M L718V	T790M L792H
E709A L858R	E709A G719S	L718Q L858R	S768_D770dup SVD L858Q	insHV	Ex19del	G724S T790M
E709K L858R	E709K	L718V	S768_D770dup SVD R958H	V774_C775	T790M G724S	L718Q T790M
E746_A750del	E709K G719S	L718V	S768_D770dup	insPR	G719A T790M	L858R T790M
A647T		Ex19del	SVD V769M		G719S T790M	C797S
E746_A750del			V769_D770ins		H773R T790M	L858R T790M
L41W	E736K	L718V L858R	ASV		I744_E749del	L718Q
E746_A750del	E746_A750del	L747_S752del	V769_D770ins		insMKK	L858R T790M
R451H	A647T	A755D	GSV		L747_K754	L718V
Ex19del	E746_A750del		V769_D770ins		delinsATSPE	
E746_A750del	R675W	L747P	GVV		L858R T790M	
K754E	E746_T751del	insV S768C	V769_D770ins		L792H	
L747_E749del		L747S	MASVD		L858R T790M	
A750P	Ex19del C797S	L747S L858R	D770_N771ins		V843I	
L747_T751del			NPG			
L861Q	Ex19del G796S	L747S V774M	D770_N771ins		L858R T790M	
L833F	Ex19del L792H	L858R C797S	SVD		S768I T790M	
L833V	Ex19del T854I	L858R L792H	D770del insGY		T790M	
L858R	G719A	L858R T854S	D770_N771			
L858R A289V	G719A D761Y	N771G	insG			
L858R E709V	G719A L861Q	R776C	D770_N771			
L858R L833F	G719A R776C	R776H	insY H773Y			
L858R P100T	G719A S768I	E709_T710del	N771dupN			
L858R P848L	G719A S768I	insD S22R	N771dupN			
L858R R108K	G719C S768I	S752_I759del	G724S			
L858R R324H	G719S	V769M	N771_P772ins			
L858R R324L	G719S L861Q	S768I	HH			
L858R S784F	G719S S768I	S768I L858R	N771_P772ins			
L858R S784Y	G724S	S768I L861Q	SVDNR			
L858R T725M	G724S Ex19del	S768I V769L	P772_H773ins			
L858R V834L	G724S L858R	S768I V774M	DNP			
L861Q	G779F	T751_I759				
L861R	I740dupIPVAK	delinsN				
S720P		V769L				
S784F		V769M				
S811F		V774M				
T725M						

Supplemental Table 5: Patient Characteristics

Mutation Type	Exon	EGFR Mutation	Age (years)	Sex	Tobacco Use (Y/N)	Pack Years	Histo Pathology	Previous Chemo (Y/N)	TKI	Stage at diagnosis
Classical Like	19	E746_A750 A750E	73	M	Y	Unknown	Adenocarcinoma	N	Erlotinib	IV
Classical Like	21	L747_T751del L861Q	59	F	Y	5	Adenocarcinoma	N	Afatinib	IV
Classical Like	21	L861Q	70	F	N	N/A	Adenocarcinoma	N	Afatinib	II
Classical Like	21	L858R E709K	59	F	Y	10	Adenocarcinoma	N	Afatinib	IV
Classical Like	21	L858R P848L	74	M	N	N/A	Adenocarcinoma	N	Osimertinib	IV
Classical Like	18	L858R T725M	52	F	N	N/A	Adenocarcinoma	N	Osimertinib	IV
Classical Like	21	L861Q	77	M	N	N/A	Adenocarcinoma	N	Osimertinib	IV
Classical Like	21	L861Q	78	M	N	N/A	Adenocarcinoma	Y	Erlotinib	IV
Classical Like	18	T725M	75	F	N	N/a	Adenocarcinoma	Y	Gefitinib	IV
Classical Like	18	A702T	62	M	Y	47	Adenocarcinoma	Y	Afatinib	IV
Classical Like	21	S811F	84	F	Y	37	Adenocarcinoma	Y	Erlotinib	IV
Classical Like	19	L747_E749del A750P	81	F	Y	8	Adenocarcinoma	N	Erlotinib	I
Classical Like	21	L861Q	70	M	Y	24	Adenocarcinoma	N	Erlotinib	IV
Classical Like	21	L861Q	73	F	N	N/A	Adenocarcinoma	N	Erlotinib	I
Classical Like	21	L858R L833F	82	M	Y	51	Adenocarcinoma	Y	Erlotinib	IV
Classical Like	18	L858R E709V	60	M	N	N/A	Adenocarcinoma	Y	Rociletinib	IV
Classical Like	19	E746_A750del A647T	56	M	N	N/A	Adenocarcinoma	Y	Erlotinib	IV
Classical Like	21	E709K L858R	70	M	Y	5	Adenocarcinoma	Y	Erlotinib	IV
Classical Like	21	L861Q	82	F	Y	Unknown	Adenocarcinoma	N	Erlotinib	IV
Classical Like	18	E709K L858R	45	M	N	N/A	Adenocarcinoma	N	Rociletinib	IV
Classical Like	21	L861Q	60	M	Y	90	Adenocarcinoma	N	Gefitinib	IV
Classical Like	21	E709K/L858R	83	F	N	N/A	Adenocarcinoma	N	Afatinib	IV
Classical Like	19	L747_E749del A750P	45	M	Y	5	Adenocarcinoma	Y	Osimertinib	III
Classical Like	21	L861Q	77	F	Y	10	Adenocarcinoma	N	Erlotinib	IV
Classical Like	19	D761Y	74	M	Y	35	Squamous cell carcinoma	Y	Afatinib	IV
Classical Like	21	L858R S784F	71	F	N	N/A	Adenocarcinoma	N	Osimertinib	IV
Classical Like	21	L858R V834L	75	F	Y	20	Adenocarcinoma	Y	Osimertinib	III
Classical Like	21	L858R L833V	60	F	N	N/A	Adenocarcinoma	Y	Osimertinib	IV
Classical Like	21	L861Q	71	F	N	N/A	Adenocarcinoma	N	Osimertinib	IV
Classical Like	18	E709A L858R	69	M	N	N/A	Adenocarcinoma	Y	Osimertinib	IV
Classical Like	21	L861Q	79	M	N	N/A	Adenocarcinoma	N	Osimertinib	IV

Classical Like	21	L858R S784Y	53	M	Y	15	Adenocarcinoma	N	Osimertinib	IV
Classical Like	6	L858R R324L	71	F	Y	32	Adenocarcinoma	Y	Erlotinib	IV
Classical Like	5	L858R A289V	57	M	N	N/A	Adenocarcinoma	N	Erlotinib	IV
Classical Like	6	L858R R324H	70	F	N	N/A	Adenocarcinoma	Y	Erlotinib	IV
Classical Like	1	L858R R108K	73	F	N	N/A	Adenocarcinoma	N	Erlotinib	IV
Classical Like	1	E746_A750del L41W	59	F	N	N/A	Adenocarcinoma	N	Gefitinib	IV
Classical Like	1	L858R P100T	65	M	Y	43	Adenocarcinoma	N	Gefitinib	IV
Classical Like	9	E746_A750del R451H	57	F	N	N/A	Adenocarcinoma	N	Erlotinib	IV
Ex20LoopIns	20	S768_D770dupSVD R958H	69	F	Unknown	1	Adenocarcinoma	Y	Poziotinib	I
		S768_D770dupSVD V769M	63	M	N	N/A	Adenocarcinoma	Y	Poziotinib	IV
Ex20LoopIns	20	S768_D770dupSVD L858Q	50	M	N	N/A	Adenocarcinoma	Y	Poziotinib	IV
Ex20LoopIns	20	Exon 20 insertion	63	F	N	N/A	Adenocarcinoma	N	Osimertinib	IV
Ex20LoopIns	20	H773_V774insH	60	M	N	NA	Adenocarcinoma	Y	Erlotinib	IV
Ex20LoopIns	20	A767_v769dupASV	61	F	N	NA	Adenocarcinoma	Y	Erlotinib	IV
Ex20LoopIns	20	D770_N771insG	49	F	N	NA	Adenocarcinoma	Y	Afatinib	IV
Ex20LoopIns	20	N771delinsGY	79	M	N	NA	Adenocarcinoma	Y	Erlotinib	IV
Ex20LoopIns	20	S768_D770dupSVD	47	F	N	NA	Adenocarcinoma	N	Erlotinib	IV
Ex20LoopIns	20	A767_V769dupASV	69	M	Y	35	Adenocarcinoma	Y	Afatinib	IV
Ex20LoopIns	20	S768_D770dupSVD	65	M	Y	0.75	Adenocarcinoma	N	Erlotinib	IV
Ex20LoopIns	20	S768_V769delinsIL	57	F	Y	<5	Adenocarcinoma	Y	Afatinib	IV
Ex20LoopIns	20	S768_D770dupSVD	56	F	N	NA	Adenocarcinoma	N	Erlotinib	IV
PACC	18	G719S	65	F	Y	60	Adenocarcinoma	N	Osimertinib	III
PACC	18	G719A S768I	47	M	N	N/A	Adenocarcinoma	N	Erlotinib	IV
PACC	18	G719S S768I	43	F	Y	2	Adenocarcinoma	N	Afatinib	I
PACC	19	L858R K757M	60	F	Y	5	Adenocarcinoma	N	Erlotinib	I
PACC	18	G719S L861Q	55	F	Y	10	Adenocarcinoma	Y	Gefitinib	III
PACC	18	G719A	85	M	Y	50	Adenocarcinoma	N	Afatinib	IV
PACC	18	G719A	66	F	Y	12	Adenocarcinoma	N	Osimertinib	IV
PACC	19	L747_S752del A755D	62	F	Y	25	Adenocarcinoma	N	Osimertinib	IV
PACC	20	V769M	89	M	Y	45	Adenosquamous	N	Osimertinib	IV
PACC	18	E709_T719del insD	78	F	N	N/A	Adenocarcinoma	N	Afatinib	IV
PACC	18	G719A	62	M	Y	10	Adenocarcinoma	Y	Erlotinib	IV
PACC	21	L858R T854S	71	F	Y	Unknown	Adenosquamous	N	Afatinib	IV

PACC	18	G719C S768I	70	F	Y	15	Adenocarcinoma	N	Erlotinib	IV
PACC	20	L858R S768I	82	M	Y	45	Adenocarcinoma	Y	Afatinib	III
PACC	20	L858R S768I	85	F	N	N/A	Adenocarcinoma	N	Osimertinib	IV
PACC	18	G719A	78	M	Y	24	Adenocarcinoma	N	Afatinib	IV
PACC	18	G719S S768I	74	M	N	N/A	Adenocarcinoma	N	Erlotinib	IV
PACC	19	L858R L747S	69	M	N	N/A	Adenocarcinoma	N	Erlotinib	IV
PACC	20	E746_T751delinsV S768C	74	F	N	N/A	Adenocarcinoma	N	Erlotinib	IV
PACC	18	E709A G719A	74	M	Y	chewing tobacco	Adenocarcinoma	Y	Afatinib	IV
PACC	20	S752_I759del V769M	64	M	N		Adenocarcinoma	Y	Erlotinib	IV
PACC	18	G719S S768I	75	F	N	N/A	Adenocarcinoma	N	Erlotinib	IV
PACC	18	G719A S768I	60	M	Y	90	Adenocarcinoma	Y	Erlotinib	IV
PACC	18	G719A S768I	66	M	N	N/A	Adenocarcinoma	Y	Poziotinib	IV
PACC	18	G719A S768I	66	M	N	N/A	Adenocarcinoma	Y	Avitinib	IV
PACC	18	E709_T710delinsD S22R	80	M	Y	22	Adenocarcinoma	Y	Afatinib	I
PACC	19	E746_A750del R675W	66	M	N	N/A	Adenocarcinoma	Y	Erlotinib	IV
PACC	18	G719A	69	F	N	N/A	Adenocarcinoma	N	Erlotinib	IV
PACC	19	E736K	59	F	Y	14.5	Adenocarcinoma	Y	Gefitinib	III
PACC	18	G719A S768I	75	F	Y	17	Adenocarcinoma	Y	Afatinib	III
PACC	18	E709_T710delinsD	66	M	N	N/A	Adenocarcinoma	Y	Afatinib	III
PACC	18	G719A	66	M	Y	25	Adenocarcinoma	Y	Afatinib	III
PACC	18	G719A	68	F	Y	25	Adenocarcinoma	N	Afatinib	III
PACC	19	T751_I759delinsN	59	F	N	N/A	Adenocarcinoma	Y	Gefitinib	IV
PACC	20	L861Q S768I	56	F	Y	38	Adenocarcinoma	Y	Afatinib	IV
PACC	19	L747S V774M	49	F	Y	15	Adenocarcinoma	N	Afatinib	IV
PACC	20	G719A R776C	52	F	N	N/A	Adenocarcinoma	N	Erlotinib	IV
PACC	18	E709K G719S	62	F	N	N/A	Adenocarcinoma	N	Afatinib	IV
PACC	20	N771G	60	F	N	N/A	Adenocarcinoma	N	Poziotinib	IV
PACC	18	G719A	87	F	Y	17.5	Adenocarcinoma	Y	Osimertinib	IV
PACC	18	E709K G719S	84	F	N	N/A	Adenocarcinoma	Y	Afatinib	IV
PACC	18	G719A	67	M	N	N/A	Adenosquamous	N	Afatinib	III
PACC	20	G779F	71	F	Y	24	Adenocarcinoma	Y	Afatinib	IV
PACC	19	T751_I759delinsN	74	F	Y	1	Adenocarcinoma	Y	Osimertinib	IV
PACC	19	L747P	63	F	N	N/A	Adenocarcinoma	N	Osimertinib	I
PACC	18	G719S S768I	62	M	N	N/A	Adenocarcinoma	Y	Afatinib	IV

PACC	19	A750_I759delinsPN	51	F	Y	13	Squamous cell carcinoma	Y	Osimertinib	IV
PACC	18	G719A D761Y	67	F	Y	32	Adenocarcinoma	Y	Osimertinib	II
PACC	20	S768I	64	F	Y	15	Adenocarcinoma	N	Afatinib	IV
PACC	18	E709A G719S	45	F	N	N/A	Adenocarcinoma	N	Afatinib	IV
PACC	18	G719S L861Q	66	M	N	N/A	Adenocarcinoma	N	Afatinib	IV
PACC	18	G719A	68	F	N	N/A	Adenocarcinoma	Y	erlotinib	IV
PACC	18	G719A	71	F	N	N/A	Large Neuroendocrine	N	Afatinib	IV
T790M-like-3S	18	G719S T790M	62	F	N	N/A	Adenocarcinoma	N	Osimertinib	IV
T790M-like-3S	20	H773R T790M	50	F	N	N/A	Adenocarcinoma	Y	Osimertinib	IV
T790M-like-3S	18	G719A T790M	60	F	N	N/A	Adenocarcinoma	N	Osimertinib	IV
T790M-like-3S	19	I744_E749delinsMKK	60	F	N	N/A	Adenocarcinoma	N	Osimertinib	IV

Supplemental Table 6: Patient Characteristics stratified by EGFR mutation type

Clinical factors	Classical-Like	PACC	Ex20LoopIns	T790M-like	<i>P</i> ^a
Total n (%)	39 (36)	53 (49)	13 (12)	4 (3)	
Age, y, median (range)	70 (45-84)	66 (43-89)	61(47-79)	60 (50-62)	> 0.9999
< 65	14 (36)	20 (38)	9 (69)	4	
≥65	25 (64)	33 (62)	4 (31)	0	
Sex n (%)					0.3934
Male	19 (49)	20 (38)	6 (46)	0	
Female	20 (51)	33 (62)	7 (54)	4	
Smoking status n (%)					0.6733
Smokers	18 (46)	28 (53)	3 (23)	0	
Nonsmokers	21 (54)	25 (47)	9 (69)	4	
Unknown	0	0	1 (8)	0	
Stage n (%)					0.1268
I-III	5 (13)	14 (26)	1 (8)	0	
IV	34 (87)	39 (74)	12 (92)	4	
Histology n (%) ^b					> 0.9999
ADC	38 (97)	48 (90)	13	4	
SCC	1 (3)	1 (2)	0	0	
ASC	0	3 (6)	0	0	
LCNEC	0	1 (2)	0	0	

The associations of EGFR mutation type with clinical variables were evaluated by Fisher's exact test. Statistical significance was considered for *p* < 0.05 and all tests were two-tailed.

^aComparison between Classical Like and PACC

^bComparison between ADC and SCC

Supplemental Table 7: EGFR mutant vectors used to generate cell lines

EGFR Mutation	Starting Vector	Genomic change	Manufacturer	Purchased / Created
Ex19del (E746_A750del)	N/A	N/A	Addgene #32062	Purchased
WT	N/A	N/A	Addgene #11011	Purchased
L858R	N/A	N/A	Addgene #11012	Purchased
G719S	N/A	N/A	Addgene #11013	Purchased
D770insNPG	N/A	N/A	Addgene #11016	Purchased
A767insASV	N/A	N/A	Addgene #32066	Purchased
L861Q	N/A	N/A	Addgene #32068	Purchased
T790M	N/A	N/A	Addgene #32070	Purchased
Ex19del T790M	N/A	N/A	Addgene #32072	Purchased
L858R/T790M	N/A	N/A	Addgene #32073	Purchased
A763insFQEAA	EGFR WT	c.2290_2291insTCCA GGAAGCCT	Bioinnovatise	Created
A767insTLA	EGFR WT	c.2302_2303insCGCT GGCCA	Bioinnovatise	Created
D770del insGY	EGFR WT	c.2308_2309insGTT	Bioinnovatise	Created
D770insG	EGFR WT	c.2310_2311insGGT	Bioinnovatise	Created
D770insY H773Y	EGFR WT	c.2310_2311insTAC and c.2317C>T	Bioinnovatise	Created
Ex19del C797S	EGFR Ex19del	c.2386, T>A	Bioinnovatise	Created
Ex19del L718Q	EGFR Ex19del	c.2153T>A	Bioinnovatise	Created
Ex19del L718V	EGFR Ex19del	c.2152C>G	Bioinnovatise	Created
Ex19del L792H	EGFR Ex19del	c.2375T>A	Bioinnovatise	Created
Ex19del T790M C797S	EGFR Ex19del T790M	c.2386, T>A	Bioinnovatise	Created
Ex19del T790M G724S	EGFR Ex19del T790M	c.2313_2314insAAC	Bioinnovatise	Created
Ex19del T790M L718V	EGFR Ex19del T790M	c.2152C>G	Bioinnovatise	Created
Ex19del T790M L792H	EGFR Ex19del T790M	c.2375T>A	Bioinnovatise	Created
G719A	EGFR WT	c.2156G>C	Bioinnovatise	Created
G719A L861Q	EGFR G719A	c.2582T>A	Bioinnovatise	Created
G719A T790M	EGFR T790M	c.2156G>C	Bioinnovatise	Created
H773insAH	EGFR WT	c.2320_2321insCCCA CG	Bioinnovatise	Created
H773insH	EGFR WT	c.2319_2320insCAC	Bioinnovatise	Created
H773insNPH	EGFR WT	c.2319_2320insAACCC CCCAC	Bioinnovatise	Created
I740dupIPVAK	EGFR WT	c.2214_2221dup	Bioinnovatise	Created
L858R C797S	EGFR L858R	c.2386, T>A	Bioinnovatise	Created
L858R L792H	EGFR L858R	c.2375T>A	Bioinnovatise	Created
L858R T790M C797S	EGFR L858R T790M	c.2386, T>A	Bioinnovatise	Created
L858R T790M L792H	EGFR L858R T790M	c.2375T>A	Bioinnovatise	Created
L858R V834L	EGFR L858R	c.2500G>T	Bioinnovatise	Created
N771insHH	EGFR WT	c.2314_2315insACCA CC	Bioinnovatise	Created
N771insSVDNR	EGFR WT	c.2312_2315ACCC>gc gtggacaaccg	Bioinnovatise	Created
P772insDNP	EGFR WT	c.2316_2317ins gacaacccc	Bioinnovatise	Created

S768dupSVD	EGFR WT	c.2303_2304dupAGCG TGGAC	Bioinnovatise	Created
S768I	EGFR WT	c.2303G>T	Bioinnovatise	Created
S768I T790M	EGFR S768I	c.2369C>T	Bioinnovatise	Created
V769insASV	EGFR WT	c.2308_2309insCCAG CGTGG	Bioinnovatise	Created
V769insGSV	EGFR WT	c.2308_2309insGCAG CGTGG	Bioinnovatise	Created
V769insGVV	EGFR WT	c.2308_2309insGGGT CGTGG	Bioinnovatise	Created
V769insMASVD	EGFR WT	c.2307_2308ins atggccagcgtggac	Bioinnovatise	Created
V769L	EGFR WT	c.2305G>T	Bioinnovatise	Created
V774insHV	EGFR WT	c.2321_2322insCCAC GT	Bioinnovatise	Created
V774insPR	EGFR WT	c.2322_2323insCCAC GT	Bioinnovatise	Created
A763insLQEA	EGFR WT	c.2289_2290insCTCC AGGAAGCC	GeneScript	Created
D761N	EGFR WT	c.2281G>A	GeneScript	Created
E709_T710del insD	EGFR WT	c.2127_2129del	GeneScript	Created
E709A	EGFR WT	c.2126A>C	GeneScript	Created
E709A G719S	EGFR G719S	c.2126A>C	GeneScript	Created
E709K	EGFR WT	c.2125G>A	GeneScript	Created
E709K G719S	EGFR G719S	c.2125G>A	GeneScript	Created
E709K L858R	EGFR L858R	c.2125G>A	GeneScript	Created
Ex19del G724S	EGFR Ex19del	c.2313_2314insAAC	GeneScript	Created
Ex19del G796S	EGFR Ex19del	c.2386G>A	GeneScript	Created
Ex19del T854I	EGFR Ex19del	c.2561C>T	GeneScript	Created
G719A/R776C	EGFR G719A	c.2326C>T	GeneScript	Created
G724S	EGFR WT	c.2170G>A	GeneScript	Created
G724S T790M	EGFR T790M	c.2313_2314insAAC	GeneScript	Created
K754E	EGFR WT	c.2260A>G	GeneScript	Created
K757R	EGFR WT	c.2270A>G	GeneScript	Created
L718Q	EGFR WT	c.2153T>A	GeneScript	Created
L718Q T790M	EGFR T790M	c.2153T>A	GeneScript	Created
L718V	EGFR WT	c.2152C>G	GeneScript	Created
L747_K754del insATSPE	EGFR WT	c.2239_2260delinsGC AACATCTCCGG	GeneScript	Created
L747P	EGFR WT	c.2239_2240TT>CC	GeneScript	Created
L747S	EGFR WT	c.2240T>C	GeneScript	Created
L833F	EGFR WT	c.2499G>T	GeneScript	Created
L833V	EGFR WT	c.2497T>G	GeneScript	Created
L858R G724S	EGFR L858R	c.2313_2314insAAC	GeneScript	Created
L858R G796S	EGFR L858R	c.2386G>A	GeneScript	Created
L858R L718Q	EGFR L858R	c.2153T>A	GeneScript	Created
L858R L718V	EGFR L858R	c.2152C>G	GeneScript	Created
L858R S784F	EGFR L858R	c.2351C>T	GeneScript	Created
L858R T790M L718Q	EGFR L858R T790M	c.2153T>A	GeneScript	Created
L858R T790M L718V	EGFR L858R T790M	c.2152C>G	GeneScript	Created

L858R T790M V843I	EGFR L858R T790M	c.2527G>A	GeneScript	Created
L861R	EGFR WT	c.2582T>G	GeneScript	Created
N771dupN G724S	EGFR G724S	c.2313_2314insAAC	GeneScript	Created
R776C	EGFR WT	c.2326C>T	GeneScript	Created
R776H	EGFR WT	c.2327G>A	GeneScript	Created
S720P	EGFR WT	c.2158T>C	GeneScript	Created
S768dupSVD V769M	EGFR S768dupSVD	c.2305G>A	GeneScript	Created
S768I V769L	EGFR S768I	c.2305G>T	GeneScript	Created
S768I V774M	EGFR S768I	c.2320G>A	GeneScript	Created
S784F	EGFR WT	c.2351C>T	GeneScript	Created
S811F	EGFR WT	c.2432C>T	GeneScript	Created
T725M	EGFR WT	c.2174C>T	GeneScript	Created
V774M	EGFR WT	c.2320G>A	GeneScript	Created